Alpine Immune Sciences

Alpine Immune Sciences EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of Alpine Immune Sciences (ALPN) as of Nov 17, 2026 is -51.94. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -95.61 — a change of -45.67% (higher).

EV/FCF

-51.94

YoY

-45.67%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Alpine Immune Sciences is 2023 -51.94 . EV/FCF (Enterprise Value to Free Cash Flow) of Alpine Immune Sciences was 2022 -95.61 . It decreases by -45.67% higher compared to the previous year.

The Alpine Immune Sciences EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2016
-166.73 USD
Jan 1, 2017
-255.31 USD
Jan 1, 2018
-152.49 USD
Jan 1, 2019
-122.24 USD
Jan 1, 2020
148.94 USD
Jan 1, 2021
-280.00 USD
Jan 1, 2022
-95.61 USD
Jan 1, 2023
-51.94 USD
The Alpine Immune Sciences EV/FCF history
YEAREV/FCFYoY
-51.94-45.67%
-95.61-65.85%
-280.00-287.99%
148.94-221.84%
-122.24-19.84%
-152.49-40.27%
-255.31+53.13%
-166.73-26.00%
-225.29-26.49%
-306.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alpine Immune Sciences Stock analysis

What does Alpine Immune Sciences do? Alpine Immune Sciences Inc. is a biopharmaceutical company specializing in the research and development of immunotherapies. Founded in 2015, the company is based in Seattle, Washington and holds numerous patents in the field of immunology. Alpine's business model is to utilize clinical science and innovative technologies to revolutionize immunotherapy. The company combines antibodies and other immunological agents to significantly improve the effectiveness and safety of therapies. The company is divided into several divisions, each offering different products and services. One division focuses on the discovery of novel antibodies and other biological agents. Through various technology platforms, Alpine continuously develops groundbreaking therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other illnesses. Another division of Alpine is dedicated to the field of immuno-oncology, specifically researching and developing immunotherapies against cancer. The main goal is to enhance the body's own immune defenses against cancer cells. Furthermore, Alpine also develops therapies for specific autoimmune diseases, where the body's immune system attacks its own cells and tissues. In this area as well, the company relies on combining different immunological agents to increase the effectiveness and safety of the therapy. One of Alpine's most well-known products is ALPN-101, a novel antibody that can be used in immunotherapy against cancer and autoimmune diseases. This antibody has the potential to improve the effectiveness and safety of existing therapies, contributing to the cure and relief of illnesses. Alpine Immune Sciences Inc. has an impressive track record, having made significant progress in the field of immunotherapy in a short period of time and establishing itself as a leading provider of innovative therapies. Additionally, Alpine has successfully formed partnerships with other companies and institutions to advance its research and development. Overall, Alpine Immune Sciences Inc. represents a forward-thinking and innovative approach to immunotherapy, with the potential to change the lives of millions of people worldwide. Alpine Immune Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpine Immune Sciences stock

EV/FCF (Enterprise Value to Free Cash Flow) of Alpine Immune Sciences is -51.94 in 2023.

EV/FCF (Enterprise Value to Free Cash Flow) of Alpine Immune Sciences changed from -95.61 to -51.94, representing a -45.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Alpine Immune Sciences since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Alpine Immune Sciences with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alpine Immune Sciences

All Key Metrics — Alpine Immune Sciences